Clinical studies reveal that TBL-12, a nutraceutical product that provides additional nutrients to the body, can also modulate the symptoms of cancer and several other diseases.
Research has shown that one third of cancer patients use alternative methods along with conventional treatments at some point during the illness. Besides moderating symptoms, these alternative methods improve their quality of life. According to clinical studies, TBL-12, which contains only natural ingredients, is said to have immense healing properties. No known side effects and no interactions with existing medications or toxins have been reported so far.
The nutraceutical product is a blend of sea cucumber, sea urchin, sea sponge, shark fin, and sargassum (free-floating seaweed). The product, harvested from the South West Pacific Region, is a clinically tested immune booster and contains powerful anti-inflammatory properties. It has a jelly-like consistency and contains protein enzyme, omega-3 fatty acids, vitamins, and minerals.
The product has been commercially available since 1981 and has been used for treating various cancers without any reported toxicity. However, those with shell-fish allergy may react adversely to it. It has been shown to possess antitumor properties, including direct tumor toxicity and anti-angiogenesis (a process that disrupts new blood vessel formation). It is believed to be effective in inducing cell growth inhibition.
Several monitored cancer patients have used and benefited from TBL-12. A patient in the late stage of multiple myeloma (cancer of the plasma cells in bone marrow) has been a key beneficiary of this product. A leukemic patient showed no signs of further progress of leukemia (blood cancer). Similarly, regression of melanoma after 3 weeks, improvement in psoriasis within a week, and recovery from prostate cancer, chronic fatigue syndrome (a condition characterized by extreme fatigue), colon cancer and incurable mesothelioma (asbestosis) have also been reported by patients who have used TBL-12.
Two clinical trials are currently in progress to assess the value of this product to treat multiple myeloma. A phase II trial reveals that high-risk untreated asymptomatic multiple myeloma patients had a decreased rate of rise of m-spike (paraprotein) concomitant with the initiation of TBL-12. This finding suggests a biologic effect of TBL-12 in multiple myeloma and warrants further study. An In Vitro study reports that TBL-12 in combination with very low dose of bortezomib (proteasome inhibitor) may have the potential to inhibit angiogenesis (a process of new blood vessel formation) and improve treatment efficacy.
Results of the current trials may serve as the basis for the use of TBL-12 in patients with early cancers or prodrome of cancers. More trials are being planned to target other cancer types and immune disorders. Currently, trials with TBL-12 are being conducted at the NYU Cancer Institute, USA. The data could serve as the basis for future trials.
See Press release: http://www.tbl-12.com/tbl-12-research-papers